The breast tumors of Asian, Black and white patients have very different cellular, microbial, and genomic features that could potentially be used to personalize care or predict disease progression, according to research by investigators at the Johns Hopkins Kimmel Cancer Center.
The DESTINY-Breast09 phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu is the first trial in more than a decade to demonstrate superior efficacy across a broad HER2-positive metastatic patient population versus current first-line standard of care.
